Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CNTX Context Therapeutics Inc.

Not Yet Opened 05-28 16:00:00 EDT

2.04

+0.04

+2.00%

盘后1.97

-0.07-3.43%

19:14 EDT

High2.12	Low1.90	Vol219.34K
Open2.00	D1 Closing2.00	Amplitude11.00%
Mkt Cap153.00M	Tradable Cap148.76M	Total Shares75.00M
T/O444.39K	T/O Rate0.30%	Tradable Shares72.92M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CNTX","market":"US","secType":"STK","nameCN":"Context Therapeutics Inc.","latestPrice":2.04,"timestamp":1716926400000,"preClose":2,"halted":0,"volume":219339,"hourTrading":{"tag":"盘后","latestPrice":1.97,"preClose":2.04,"latestTime":"19:14 EDT","volume":1927,"amount":3789.7,"timestamp":1716938046481},"delay":0,"floatShares":72921303,"shares":74998312,"eps":-1.335564,"marketStatus":"Not Yet Opened","change":0.04,"latestTime":"05-28 16:00:00 EDT","open":2,"high":2.12,"low":1.9,"amount":444385.639458,"amplitude":0.11,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.335564,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1716969600000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":1634702400000,"exchange":"NASDAQ","adjPreClose":2,"preHourTrading":{"tag":"盘前","latestPrice":2,"preClose":2,"latestTime":"08:15 EDT","volume":105,"amount":210,"timestamp":1716898520190},"postHourTrading":{"tag":"盘后","latestPrice":1.97,"preClose":2.04,"latestTime":"19:14 EDT","volume":1927,"amount":3789.7,"timestamp":1716938046481},"volumeRatio":1.366443},"requestUrl":"/m/hq/s/CNTX/wiki","defaultTab":"wiki","newsList":[{"id":"2438309256","title":"BRIEF-Nextech Crossover I SCSP Reports 9.9% Passive Stake In Context Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2438309256","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2438309256?lang=en_us&edition=fundamental","pubTime":"2024-05-25 06:31","pubTimestamp":1716589907,"startTime":"0","endTime":"0","summary":"May 24 (Reuters) - Context Therapeutics Inc   :   * NEXTECH CROSSOVER I SCSP REPORTS 9.9% PASSIVE STAKE IN CONTEXT THERAPEUTICS AS OF MAY 6- SEC FILINGSource text for Eikon:    Further company coverage:    ((reuters.briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2437053103","title":"Context Therapeutics Files Prospectus for Secondary Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2437053103","media":"MT Newswires Live","top":-1,"share":"https://ttm.financial/m/news/2437053103?lang=en_us&edition=fundamental","pubTime":"2024-05-24 22:15","pubTimestamp":1716560139,"startTime":"0","endTime":"0","summary":"Context Therapeutics  on Friday filed a registration statement with the US Securities and Exchange Commission for the sale of up to 64.5 million common shares by selling stockholders from time to time in one or more offerings.The company is not selling any common shares under the prospectus and won't get any proceeds from the sale of shares by selling shareholders, according to the filing.Price: 1.98, Change: +0.03, Percent Change: +1.28","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"gpt_icon":0},{"id":"2437035547","title":"BRIEF-Context Therapeutics Files For Shelf Of Up To 64.5 Million Shares Of Common Stock By Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2437035547","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2437035547?lang=en_us&edition=fundamental","pubTime":"2024-05-24 19:53","pubTimestamp":1716551589,"startTime":"0","endTime":"0","summary":"May 24 (Reuters) - Context Therapeutics Inc   :   * CONTEXT THERAPEUTICS FILES FOR SHELF OF UP TO 64.5 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILINGSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2437224150","title":"The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains","url":"https://stock-news.laohu8.com/highlight/detail?id=2437224150","media":"InvestorPlace","top":-1,"share":"https://ttm.financial/m/news/2437224150?lang=en_us&edition=fundamental","pubTime":"2024-05-23 08:50","pubTimestamp":1716425447,"startTime":"0","endTime":"0","summary":"Biotechs can see triple-digit returns or dramatic losses but these Piper Sandler stocks have the potential to achieve them.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://investorplace.com/2024/05/the-100-club-piper-sandlers-3-top-picks-for-triple-digit-gains/","is_publish_highlight":false,"gpt_icon":0},{"id":"2437948599","title":"Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice","url":"https://stock-news.laohu8.com/highlight/detail?id=2437948599","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2437948599?lang=en_us&edition=fundamental","pubTime":"2024-05-21 00:00","pubTimestamp":1716220810,"startTime":"0","endTime":"0","summary":"Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be \"buying high, but hoping to sell even higher.\" With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even though momentum is a popular stock characteristic, it can be tough to define. Debate surrounding which are the best and worst metrics to focus on is lengthy, but the Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.Investors should also pay attention to CNTX's average 20-day trading volume. Volume is a useful item in many ways, and the 20-day average establishes a good price-to-volume baseline; a rising stock with above average volume is generally a bullish sign, whereas a declin","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/F3nzpi36wi9juoO_v9PrEA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2a50596f066181e48e4ae0ad6be00462","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/F3nzpi36wi9juoO_v9PrEA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2a50596f066181e48e4ae0ad6be00462"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/looking-top-momentum-pick-why-160010041.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435062348","title":"Optimistic Outlook for Context Therapeutics’ CTIM-76 Based on Targeting Efficacy and Market Potential","url":"https://stock-news.laohu8.com/highlight/detail?id=2435062348","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435062348?lang=en_us&edition=fundamental","pubTime":"2024-05-16 15:55","pubTimestamp":1715846138,"startTime":"0","endTime":"0","summary":"Joseph Catanzaro, an analyst from Piper Sandler, has initiated a new Buy rating on Context Therapeutics (CNTX). Joseph Catanzaro’s rating is based ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/optimistic-outlook-for-context-therapeutics-ctim-76-based-on-targeting-efficacy-and-market-potential?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/optimistic-outlook-for-context-therapeutics-ctim-76-based-on-targeting-efficacy-and-market-potential?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435115541","title":"Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2435115541","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2435115541?lang=en_us&edition=fundamental","pubTime":"2024-05-15 00:00","pubTimestamp":1715702408,"startTime":"0","endTime":"0","summary":"Context Therapeutics Inc.  appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 . An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.Therefore, the Zacks rating upgrade for Context Therapeutics Inc. basically reflects positivity about its earnings outlook that could translate into buying pressure a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/bHsRpCKrGzzbaGHEolBtWw--~B/aD02MTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/bHsRpCKrGzzbaGHEolBtWw--~B/aD02MTg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/023168c7ea091c342492be3899b280af"],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/context-therapeutics-inc-cntx-upgraded-160008735.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2434456899","title":"BRIEF-Deep Track Capital Reports Passive Stake Of 9.89% In Context Therapeutics As Of May 2, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2434456899","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2434456899?lang=en_us&edition=fundamental","pubTime":"2024-05-11 04:34","pubTimestamp":1715373289,"startTime":"0","endTime":"0","summary":"May 10 (Reuters) -    Deep Track Capital:   * DEEP TRACK CAPITAL, LP REPORTS PASSIVE STAKE OF 9.89% IN CONTEXT THERAPEUTICS AS OF MAY 2, 2024- SEC FILINGSource text for Eikon:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2434671770","title":"Promising Clinical Trials and Strong Financial Position Support Buy Rating for Context Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2434671770","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2434671770?lang=en_us&edition=fundamental","pubTime":"2024-05-09 18:35","pubTimestamp":1715250942,"startTime":"0","endTime":"0","summary":"Context Therapeutics (CNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar fr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-clinical-trials-and-strong-financial-position-support-buy-rating-for-context-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-clinical-trials-and-strong-financial-position-support-buy-rating-for-context-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2434770620","title":"Context Therapeutics Reports First Quarter 2024 Operating and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2434770620","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2434770620?lang=en_us&edition=fundamental","pubTime":"2024-05-09 04:06","pubTimestamp":1715198760,"startTime":"0","endTime":"0","summary":"Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76. Completed $100 million financing; expected to extend funding into 2028. PHILADELPHIA, May 08, 2024  -- Context Therapeutics Inc.  , a biopharmaceutical company advancing medicines for solid tumors, today announced its financial results for the first quarter ended March 31, 2024, and reported on recent business highlights.In May 2024, Context announced a private placement that resulted in gross proceeds of approximately $100 million, before deducting placement agent fees and estimated offering expenses.Research and development  expenses were $2.0 million for the first quarter 2024, as compared to $4.5 million for the same period in 2023. The decrease in R&D expenses was primarily driven by lower onapristone extended release  expenses, mostly due to the Company’s decision in March 2023 to discontinue the development of ONA-XR, as well as lower CTIM-76 contract manufacturing costs and personnel-related exp","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/IdoONhPWxMgW8UNRadv3bQ--~B/aD0yMjY7dz00ODU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2ecf57f3dc7765bd8c5cadbf95373ccc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/IdoONhPWxMgW8UNRadv3bQ--~B/aD0yMjY7dz00ODU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2ecf57f3dc7765bd8c5cadbf95373ccc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/context-therapeutics-reports-first-quarter-200600177.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432971147","title":"AEON, SGBX and APVO among pre-market losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2432971147","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432971147?lang=en_us&edition=fundamental","pubTime":"2024-05-03 20:36","pubTimestamp":1714739809,"startTime":"0","endTime":"0","summary":"Losers: AEON Biopharma  -46% announces preliminary top-line results from phase 2 interim analysis of ABP-450 in the preventive treatment of chronic migraine. Sprout Social  -29% after Q1 earnings release. Marin Software  -19% after Q1 earnings release. Stem  -19% shows Q1 results. Terran Orbital Corp  -17% as Lockheed Martin withdraws takeover offer.  Cloudflare  -14% after Q1 earnings release. BigBear.ai Holdings  -12% after Q1 earnings release. Expedia Group  -11% after Q1 earnings release. Cardiff Oncology  -11% after Q1 earnings release. Aptevo Therapeutics  -12%. Context Therapeutics  -9%. Fortinet  -8% beats Q1 estimates. Safe & Green Holdings Corp  -7%. LQR House  -6%.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4099565-aeon-sgbx-and-apvo-among-pre-market-losers","is_publish_highlight":false,"gpt_icon":0},{"id":"2432883922","title":"Buy Rating Affirmed for Context Therapeutics Amid Promising CTIM-76 Developments and Competitive Edge","url":"https://stock-news.laohu8.com/highlight/detail?id=2432883922","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432883922?lang=en_us&edition=fundamental","pubTime":"2024-05-03 18:29","pubTimestamp":1714732155,"startTime":"0","endTime":"0","summary":"Emily Bodnar, an analyst from H.C. Wainwright, maintained the Buy rating on Context Therapeutics (CNTX – Research Report). The associated price tar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-context-therapeutics-amid-promising-ctim-76-developments-and-competitive-edge?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-affirmed-for-context-therapeutics-amid-promising-ctim-76-developments-and-competitive-edge?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2432602351","title":"CytomX Therapeutics, Allarity Therapeutics, Pulmonx among healthcare movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2432602351","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432602351?lang=en_us&edition=fundamental","pubTime":"2024-05-02 22:00","pubTimestamp":1714658443,"startTime":"0","endTime":"0","summary":"Gainers: Allarity Therapeutics  +107%. Emergent Biosolutions  +66%. Pulmonx  +26%. Context Therapeutics  +25%. Lantheus Holdings  +17%.  Losers: Accuray  -21%. Metagenomi  -16%. Atricure  -16%. CytomX Therapeutics  -12%. Elevation Oncology  -12%.  S&P 500 Health Care Sector -0.21% to 1635.09. Health Care Equipment & Services -0.15% to 1889.78. Pharmaceuticals, Biotechnology & Life Science which contributes 58% to index is -0.27% to 1343.2.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4098640-cytomx-therapeutics-allarity-therapeutics-pulmonx-among-healthcare-movers","is_publish_highlight":false,"gpt_icon":0},{"id":"2432608733","title":"NOVA, STI and SGMT are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2432608733","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432608733?lang=en_us&edition=fundamental","pubTime":"2024-05-02 20:43","pubTimestamp":1714653794,"startTime":"0","endTime":"0","summary":"Gainers: Allarity Therapeutics  +133% Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer.  Emergent Biosolutions  +54% gains as results top estimates, co to cut 300 jobs.  Carvana  +37% rips a 35% gains after J.P. Morgan upgrade adds to the earnings buzz  Context Therapeutics  +35% stock jumps on $100M private placement.  Aspen Aerogels  +30% Q1 earnings call release  Enovix Corporation  +29% q1 earnings call release  Pulmonx  +23% Q1 earnings call release  Wayfair  +19% Q1 earnings call release  Sagimet Biosciences  +17%. Rush Street Interactive  +15% Q1 earnings call release  Peloton Interactive  +13% Q3 earnings call release  Organogenesis Holdings  +12% Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis.  Bon Natural Life  +11%. Solidion Technology  +11%. Sunnova Energy International  +11% Q1 earnings call release","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4098484-nova-sti-and-sgmt-are-among-premarket-gainers","is_publish_highlight":false,"gpt_icon":0},{"id":"2432672922","title":"Context Therapeutics stock jumps on $100M private placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2432672922","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432672922?lang=en_us&edition=fundamental","pubTime":"2024-05-02 20:00","pubTimestamp":1714651204,"startTime":"0","endTime":"0","summary":"Context Therapeutics  shares leaped 69% in pre-market trade, after the firm said it is looking to raise $100 million through a private placement. The private placement includes the sale of an aggregate of ~64.5 million shares or pre-funded warrants at $1.55 apiece. The company said each pre-funded warrant will have an exercise price of $0.001 per share of common stock, will be immediately exercisable and will not expire. The price per share is at a 14% premium to the firm's last close on Wednesday. The firm expects that the net proceeds, together with its existing cash and cash equivalents, to extend its cash runway through the estimated duration of its planned CTIM-76 Phase 1 clinical trial, as well as into 2028.","market":"nz","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1275445415/image_1275445415.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1275445415/image_1275445415.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4098427-context-therapeutics-stock-jumps-on-100m-private-placement","is_publish_highlight":false,"gpt_icon":0},{"id":"2432671736","title":"BRIEF-Context Therapeutics Expects To Enroll First Patient Mid-2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2432671736","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432671736?lang=en_us&edition=fundamental","pubTime":"2024-05-02 19:42","pubTimestamp":1714650159,"startTime":"0","endTime":"0","summary":"May 2  - Context Therapeutics Inc   :   * CONTEXT THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR A PHASE 1 CLINICAL TRIAL OF CTIM-76   * CONTEXT THERAPEUTICS: COMPANY EXPECTS TO ENROLL FIRST PATIENT IN MID-2024Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2432679019","title":"Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76","url":"https://stock-news.laohu8.com/highlight/detail?id=2432679019","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2432679019?lang=en_us&edition=fundamental","pubTime":"2024-05-02 19:31","pubTimestamp":1714649460,"startTime":"0","endTime":"0","summary":"CTIM-76 Phase 1 clinical trial to focus on CLDN6-positive gynecologic and testicular cancers. Company expects to enroll first patient in mid-2024. PHILADELPHIA, May 02, 2024  -- Context Therapeutics Inc.  , a biopharmaceutical company advancing medicines for solid tumors, today announced that the U.S. Food and Drug Administration  has cleared its Investigational New Drug  application for CTIM-76, a Claudin 6  x CD3 T cell engaging bispecific antibody. The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of CTIM-76 in patients with CLDN6-positive gynecologic and testicular cancers. The Company anticipates the enrollment of the first patient in the dose escalation portion of its clinical trial in mid-2024.Forward-looking StatementsThis press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Sec","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/IdoONhPWxMgW8UNRadv3bQ--~B/aD0yMjY7dz00ODU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2ecf57f3dc7765bd8c5cadbf95373ccc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/IdoONhPWxMgW8UNRadv3bQ--~B/aD0yMjY7dz00ODU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2ecf57f3dc7765bd8c5cadbf95373ccc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/context-therapeutics-announces-fda-clearance-113100773.html","is_publish_highlight":false,"gpt_icon":1},{"id":"2432679094","title":"Context Therapeutics Announces $100 Million Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2432679094","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2432679094?lang=en_us&edition=fundamental","pubTime":"2024-05-02 19:30","pubTimestamp":1714649400,"startTime":"0","endTime":"0","summary":"Financing includes new and existing leading healthcare investors. Proceeds, along with existing cash and cash equivalents, are expected to extend cash runway into 2028. PHILADELPHIA, May 02, 2024  -- Context Therapeutics Inc.  , a biopharmaceutical company advancing medicines for solid tumors, today announced that it has entered into a securities purchase agreement with certain new and existing investors in a private placement that is expected to result in gross proceeds of approximately $100.0 million, before deducting placement agent fees and estimated offering expenses. The private placement is expected to close on May 6, 2024, subject to the satisfaction of customary closing conditions.The private placement is led by new investor Nextech1, with participation from new and existing investors, including Ally Bridge Group, Avidity Partners, Blackstone Multi-Asset Investing, Blue Owl Healthcare Opportunities, Deep Track Capital, Driehaus Capital Management, Great Point Partners, LLC, an","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/IdoONhPWxMgW8UNRadv3bQ--~B/aD0yMjY7dz00ODU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2ecf57f3dc7765bd8c5cadbf95373ccc","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/IdoONhPWxMgW8UNRadv3bQ--~B/aD0yMjY7dz00ODU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2ecf57f3dc7765bd8c5cadbf95373ccc"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/context-therapeutics-announces-100-million-113000798.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2426838293","title":"Buy Rating on Context Therapeutics’s CTIM-76 Bolstered by Market Validation and Competitive Edge","url":"https://stock-news.laohu8.com/highlight/detail?id=2426838293","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2426838293?lang=en_us&edition=fundamental","pubTime":"2024-04-12 01:15","pubTimestamp":1712855732,"startTime":"0","endTime":"0","summary":"Context Therapeutics (CNTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCar...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/buy-rating-on-context-therapeuticss-ctim-76-bolstered-by-market-validation-and-competitive-edge?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/buy-rating-on-context-therapeuticss-ctim-76-bolstered-by-market-validation-and-competitive-edge?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2424945714","title":"Context Therapeutics rises on submission of IND application for its Claudin 6-positive cancers treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2424945714","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2424945714?lang=en_us&edition=fundamental","pubTime":"2024-04-01 21:11","pubTimestamp":1711977104,"startTime":"0","endTime":"0","summary":"Context Therapeutics  shares up about 5% premarket after the company said that it submitted an Investigational New Drug application to the FDA to begin a first-in-human clinical study of CTIM-76.The IND supports the initiation of a Phase 1 dose escalation and expansion clinical trial of CTIM-76 in patients with Claudin 6 -positive gynecologic and testicular cancers. Source: Press Release. More on Context Therapeutics  Seeking Alpha’s Quant Rating on Context Therapeutics Historical earnings data for Context Therapeutics Financial information for Context Therapeutics","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4085592-context-therapeutics-rises-on-submission-of-ind-application-for-its-claudin-6-positive-cancers-treatment","is_publish_highlight":false,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.contexttherapeutics.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.5385},{"period":"3month","weight":0.7241},{"period":"6month","weight":1.3092},{"period":"1year","weight":1.381},{"period":"ytd","weight":0.7699}],"compareEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.0475},{"period":"3month","weight":0.0425},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.2768},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.","exchange":"NASDAQ","name":"Context Therapeutics Inc.","nameEN":"Context Therapeutics Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Context Therapeutics Inc.(CNTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Context Therapeutics Inc.,CNTX,Context Therapeutics Inc.股票,Context Therapeutics Inc.股票老虎,Context Therapeutics Inc.股票老虎国际,Context Therapeutics Inc.行情,Context Therapeutics Inc.股票行情,Context Therapeutics Inc.股价,Context Therapeutics Inc.股市,Context Therapeutics Inc.股票价格,Context Therapeutics Inc.股票交易,Context Therapeutics Inc.股票购买,Context Therapeutics Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Context Therapeutics Inc.(CNTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Context Therapeutics Inc.(CNTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction